Fortress Biotech, Inc. FBIO was a big mover last session, as its shares rose almost 21% on the day. The move came after the company reported breakthrough with CAR-T cancer approach. This led to far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $1.95 to $2.43 in the past one-month time frame.
None of the estimates for this stock were revised over the past 30 days. The Zacks Consensus Estimate also remained unchanged over the same time frame. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Fortress Biotech currently carries a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.
FORTRESS BIOTEC Price
FORTRESS BIOTEC Price | FORTRESS BIOTEC Quote
A better-ranked stock in the medical-biomedical and genetics space is Arbutus Biopharma Corporation ABUS, sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks' Top Investment Ideas for Long-Term Profit
How would you like to see our best recommendations to help you find today’s most promising long-term stocks? Starting now, you can look inside our portfolios featuring stocks under $10, income stocks, value investments and more. These picks, which have double and triple-digit profit potential, are rarely available to the public. But you can see them now. Click here >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ARBUTUS BIOPH (ABUS): Free Stock Analysis Report
FORTRESS BIOTEC (FBIO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research